文献速递呼吸道感染

流感后CA-MRSA肺炎六例分子流行病学与临床特征

[Molecular epidemiology and clinical characteristics of six cases of CA-MRSA pneumonia after influenza].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2023-01-01

该研究回顾性分析2014—2022年6例流感后社区获得性耐甲氧西林金黄色葡萄球菌(CA-MRSA)肺炎病例,对分离菌株行SCCmec、MLST及spa分型、毒力因子检测和药敏试验。结果ST59-t437-Ⅳ为主要分型(2/6),PVL检出5例,5例为重症肺炎,万古霉素首选治疗均好转出院。提示流感后CA-MRSA感染多见于年轻无基础疾病人群,可致重症肺炎。

要点

  • 流感后CA-MRSA肺炎分子分型及毒力因子多样,ST59-t437-Ⅳ为主(2/6)。
  • 6例中5例为重症肺炎,5例首选万古霉素抗感染治疗且病情好转出院。
  • 流感后重症肺炎应及时送病原学检测明确CA-MRSA感染并给予相应治疗。

核心结论

  • 流感后CA-MRSA分子分型及携带的毒力因子多样。
  • 流感后继发CA-MRSA感染更常见于年轻、既往无基础疾病人群,可引起重症肺炎。
  • 流感后合并重症肺炎患者需及时送病原学检测明确是否为CA-MRSA感染,给予抗流感病毒及抗CA-MRSA感染治疗。

研究设计与样本

  • 回顾性分析2014—2022年6例流感后CA-MRSA肺炎病例,分离培养6株CA-MRSA。
  • 对6株菌行SCCmec分型、MLST分型及spa分型,检测毒力因子并进行药物敏感性实验。

主要发现

  • 6株CA-MRSA中ST59-t437-Ⅳ型为主要分型(2/6)。
  • 杀白细胞素(PVL)检出5例,溶血素α(HLAα)及酚溶性调节蛋白α(PSMα)检出6例。
  • 6例患者中5例为重症肺炎。
  • 治疗上4例接受过抗病毒治疗,5例重症肺炎患者均首选万古霉素抗感染治疗且病情好转出院。

关键数值与推荐

  • ST59-t437-Ⅳ型为主要分型(2/6)。
  • PVL检出5例,HLAα及PSMα检出6例。
  • 5例为重症肺炎,5例重症肺炎患者首选万古霉素抗感染治疗。

临床怎么用

  • 流感后重症肺炎患者应及时送病原学检测以明确是否为CA-MRSA感染。
  • 明确CA-MRSA感染后应给予抗流感病毒及抗CA-MRSA感染治疗。
  • 万古霉素和利奈唑胺为治疗CA-MRSA感染的一线药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To summarize and analyze the strains' molecular epidemiology and clinical characteristics of 6 strains of post-influenza community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) pneumonia. Methods: Six cases of CA-MRSA pneumonia after influenza from 2014 to 2022 were retrospectively collected and CA-MRSA strains from each patient were cultured. Then, SCCmec typing, MLST typing, and spa typing were performed on the samples, which also included the procedures for the detection of virulence factors. Antibiotic susceptibility test was then performed on all 6 strains. Results: ST59-t437-Ⅳ was the predominant type in all the strains of CA-MRSA(2/6). Leukocidin (PVL) was detected in 5 cases, and hemolysin α (HLAα) and phenol soluble regulatory protein α (PSMα) were detected in 6 cases. Five of the cases included in this study were diagnosed with severe pneumonia. In terms of treatment, 4 cases received antiviral therapy, and 5 patients with severe pneumonia received anti-infection treatment with vancomycin as the first choice and were discharged after improvement of their condition. Conclusions: The molecular types and virulence factors of CA-MRSA after influenza infection could vary considerably. Our experiments also showed that secondary CA-MRSA infection after influenza was more common in young people with no underlying diseases and could cause severe pneumonia. Vancomycin and linezolid were the first-line drugs for treating CA-MRSA infection and were highly effective in improving the condition of diagnosed patients. We highlighted the importance of referring patients with severe pneumonia after influenza for etiological tests to determine whether they had CA-MRSA infection, so that they could be properly treated with anti-influenza agents and receive appropriate anti-CA-MRSA infection treatment. 目的: 分析流感后社区获得性耐甲氧西林金黄色葡萄球菌(CA-MRSA)感染病例的分子流行病学及临床特征。 方法: 回顾性分析2014—2022年6例流感后CA-MRSA肺炎的病例,分离培养6株CA-MRSA,进行3种分子流行病学分型(SCCmec分型、MLST分型及spa分型)、检测其毒力因子并进行药物敏感性实验;总结病例临床特征及诊疗过程。 结果: 6株CA-MRSA中ST59-t437-Ⅳ型为主要分型(2/6);杀白细胞素(PVL)检出5例,溶血素α(HLAα)及酚溶性调节蛋白α(PSMα)检出6例。6例患者中5例为重症肺炎;治疗上,4例接受过抗病毒治疗,5例重症肺炎患者均首选万古霉素抗感染治疗且病情好转出院。 结论: 流感后的CA-MRSA分子分型及携带的毒力因子多样;流感后继发CA-MRSA感染更常见于年轻、既往无基础疾病人群,可引起重症肺炎。流感后合并重症肺炎患者需要及时送病原学检测明确是否为CA-MRSA感染,给予抗流感病毒及抗CA-MRSA感染治疗。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhong JJ, Wei M, Yang CX, et al. [Molecular epidemiology and clinical characteristics of six cases of CA-MRSA pneumonia after influenza]. Zhonghua Jie He He Hu Xi Za Zhi. 2023. PMID: 37147810. doi:10.3760/cma.j.cn112147-20220926-00782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。